Estimation of the Additional Budget Saving Potential Due to the Rapid Adoption of An Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Spain
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.743
https://www.valueinhealthjournal.com/article/S1098-3015(17)31077-X/fulltext
Title :
Estimation of the Additional Budget Saving Potential Due to the Rapid Adoption of An Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31077-X&doi=10.1016/j.jval.2017.08.743
First page :
A529
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
708